{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:25:54Z","timestamp":1793190354984,"version":"4.5.0"},"posted":{"date-parts":[[2022,4,12]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":41,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Anti-spike IgG binding antibody, anti-receptor binding domain IgG antibody, and pseudovirus neutralizing antibody measurements four weeks post-vaccination were assessed as correlates of risk of moderate to severe-critical COVID-19 outcomes through 83 days post-vaccination and as correlates of protection following a single dose of Ad26.COV2.S COVID-19 vaccine in the placebo-controlled phase of ENSEMBLE, an international, randomized efficacy trial. Each marker had evidence as a correlate of risk and of protection, with strongest evidence for 50% inhibitory dilution (ID50) neutralizing antibody titer. The outcome hazard ratio was 0.49 (95% confidence interval 0.29, 0.81; p=0.006) per 10-fold increase in ID50; vaccine efficacy was 60% (43, 72%) at nonquantifiable ID50 (&lt; 2.7 IU50\/ml) and rose to 89% (78, 96%) at ID50 = 96.3 IU50\/ml. Comparison of the vaccine efficacy by ID50 titer curves for ENSEMBLE-US, the COVE trial of the mRNA-1273 vaccine, and the COV002-UK trial of the AZD1222 vaccine supported consistency of the ID50 titer correlate of protection across trials and vaccine types.<\/jats:p>","DOI":"10.1101\/2022.04.06.22272763","type":"posted-content","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T01:25:18Z","timestamp":1649813118000},"source":"Crossref","is-referenced-by-count":9,"title":["Immune Correlates Analysis of a Single Ad26.COV2.S Dose in the ENSEMBLE COVID-19 Vaccine Efficacy Clinical Trial"],"prefix":"10.64898","author":[{"given":"Youyi","family":"Fong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian B.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Benkeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Roels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Stieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Vandebosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu Le","family":"Gars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Griet A.","family":"Van Roey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Houchens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Obrimpong","family":"Amoa-Awua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Basappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Flach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob C.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mursal","family":"Naisan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed","family":"Naqvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Narpala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Serebryannyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos J.","family":"Petropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Luedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ollivier","family":"Hyrien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavesh","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars W. P.","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima S.","family":"Hejazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Carone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel N.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerald","family":"Sadoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda E.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Goepfert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan J.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Paiva de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebone","family":"Maboa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K.","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele P.","family":"Andrasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Truyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Struyf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macaya","family":"Douoguih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Kublin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0333-5925","authenticated-orcid":false,"given":"Lindsay N.","family":"Carpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Follmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Koup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben O.","family":"Donis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Janssen Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Coronavirus Vaccine Prevention Network (CoVPN)\/ENSEMBLE Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the United States Government (USG)\/CoVPN Biostatistics Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2022041501100492000_2022.04.06.22272763v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544"},{"issue":"9","key":"2022041501100492000_2022.04.06.22272763v1.2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa2117608","article-title":"Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"2022041501100492000_2022.04.06.22272763v1.3","unstructured":"US Food and Drug Administration. Janssen COVID-19 Vaccine. https:\/\/www.fda.gov\/emergency-preparedness-and-response\/coronavirus-disease-2019-covid-19\/janssen-covid-19-vaccine xLast updated 19 Jan, 2022. Access date 23 Jan, 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.4","unstructured":"World Health Organization. COVID-19 vaccines WHO EUL issued. https:\/\/extranet.who.int\/pqweb\/vaccines\/vaccinescovid-19-vaccine-eul-issued Access date 24 Jan, 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.5","unstructured":"European Commission. European Commission authorises fourth safe and effective vaccine against COVID-19. Press release. 11 March 2021. https:\/\/ec.europa.eu\/commission\/presscorner\/detail\/en\/ip_21_1085 Access date 24 Jan, 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.6","unstructured":"VIPER Group COVID19 Vaccine Tracker Team. COVID19 Vaccine Tracker. https:\/\/covid19.trackvaccines.org\/vaccines\/approved\/ Access date 24 Jan, 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.7","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10"},{"key":"2022041501100492000_2022.04.06.22272763v1.8","doi-asserted-by":"crossref","unstructured":"Plotkin SA , Gilbert PB . \u201cCorrelates of Protection\u201d in Plotkin\u2019s Vaccines (Seventh Edition). S.A. Plotkin , W.A. Orenstein , P.A. Offit , K.M. Edwards , Eds. (Elsevier, 2018), chap. 3.","DOI":"10.1016\/B978-0-323-35761-6.00003-1"},{"key":"2022041501100492000_2022.04.06.22272763v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis238"},{"key":"2022041501100492000_2022.04.06.22272763v1.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2116298"},{"key":"2022041501100492000_2022.04.06.22272763v1.11","unstructured":"US Food and Drug Administration. FDA News Release. FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age. 29 Oct, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use-children-5-through-11-years-age Access date 3 Feb, 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034545"},{"key":"2022041501100492000_2022.04.06.22272763v1.13","doi-asserted-by":"crossref","unstructured":"Addetia A , Crawford KHD , Dingens A , et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol 2020; 58(11).","DOI":"10.1128\/JCM.02107-20"},{"key":"2022041501100492000_2022.04.06.22272763v1.14","doi-asserted-by":"publisher","DOI":"10.1038\/S41586-020-03041-6"},{"key":"2022041501100492000_2022.04.06.22272763v1.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284"},{"issue":"6561","key":"2022041501100492000_2022.04.06.22272763v1.16","doi-asserted-by":"crossref","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","year":"2021","journal-title":"Science"},{"key":"2022041501100492000_2022.04.06.22272763v1.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.05.040"},{"key":"2022041501100492000_2022.04.06.22272763v1.18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109682"},{"key":"2022041501100492000_2022.04.06.22272763v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8"},{"key":"2022041501100492000_2022.04.06.22272763v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063"},{"issue":"2","key":"2022041501100492000_2022.04.06.22272763v1.21","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1056\/NEJMp2033538","article-title":"Placebo-Controlled Trials of Covid-19 Vaccines -Why We Still Need Them","volume":"384","author":"WHO Ad Hoc Expert Group on the Next Steps for Covid-19 Vaccine Evaluation","year":"2021","journal-title":"N Engl J Med"},{"key":"2022041501100492000_2022.04.06.22272763v1.22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41591-021-01484-6","article-title":"A government-led effort to identify correlates of protection for COVID-19 vaccines","volume":"27","year":"2021","journal-title":"Nature Medicine"},{"key":"2022041501100492000_2022.04.06.22272763v1.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389"},{"issue":"6576","key":"2022041501100492000_2022.04.06.22272763v1.24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","year":"2022","journal-title":"Science"},{"issue":"11","key":"2022041501100492000_2022.04.06.22272763v1.25","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","year":"2021","journal-title":"Nat Med"},{"key":"2022041501100492000_2022.04.06.22272763v1.26","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2607"},{"key":"2022041501100492000_2022.04.06.22272763v1.27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00432-3"},{"issue":"1","key":"2022041501100492000_2022.04.06.22272763v1.28","doi-asserted-by":"crossref","first-page":"23921","DOI":"10.1038\/s41598-021-03154-6","article-title":"Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation","volume":"11","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"2022041501100492000_2022.04.06.22272763v1.29","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","year":"2022","journal-title":"Lancet Microbe"},{"issue":"10","key":"2022041501100492000_2022.04.06.22272763v1.30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1056\/NEJMc2108829","article-title":"Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"key":"2022041501100492000_2022.04.06.22272763v1.31","doi-asserted-by":"crossref","unstructured":"Pajon R , Paila YD , Girard B , et al. Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. Nat Med 2022.","DOI":"10.1038\/s41591-022-01679-5"},{"key":"2022041501100492000_2022.04.06.22272763v1.32","doi-asserted-by":"crossref","unstructured":"Zhang Z , Mateus J , Coelho CH , et al. Humoral and cellular immune memory to four COVID-19 vaccines. doi: https:\/\/doi.org\/10.1101\/2022.03.18.484953 Posted 21 Mar, 2022. Access date 22 Mar, 2022. bioRxiv.","DOI":"10.1101\/2022.03.18.484953"},{"key":"2022041501100492000_2022.04.06.22272763v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100510"},{"issue":"7871","key":"2022041501100492000_2022.04.06.22272763v1.34","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans","volume":"596","year":"2021","journal-title":"Nature"},{"key":"2022041501100492000_2022.04.06.22272763v1.35","unstructured":"National Institute for Biological Standards and Control (NIBSC). Instructions for use of First WHO International Standard for anti-SARS-CoV-2 Immunoglobulin (Version 3.0, Dated 17\/12\/2020) NIBSC code: 20\/136 https:\/\/www.nibsc.org\/science_and_research\/idd\/cfar\/covid-19_reagents.aspx Access date Jul 29, 2021."},{"key":"2022041501100492000_2022.04.06.22272763v1.36","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/73.1.1"},{"key":"2022041501100492000_2022.04.06.22272763v1.37","doi-asserted-by":"crossref","unstructured":"Lumley T. Complex Surveys: A Guide to Analysis Using R (vol. 565, John Wiley & Sons, 2010).","DOI":"10.1002\/9780470580066"},{"key":"2022041501100492000_2022.04.06.22272763v1.38","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. https:\/\/www.R-project.org\/. 2022."},{"key":"2022041501100492000_2022.04.06.22272763v1.39","volume-title":"Assessment of Immune Correlates of Protection via Controlled Vaccine Efficacy and Controlled Risk","year":"2021"},{"key":"2022041501100492000_2022.04.06.22272763v1.40","year":"2021"},{"key":"2022041501100492000_2022.04.06.22272763v1.41","unstructured":"Westfall PH , Young SS . Resampling-Based Multiple Testing: Examples and Methods for P-Value Adjustment (vol. 279, Wiley Series in Probability and Statistics, John Wiley & Sons, 1993)."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.04.06.22272763","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:40:59Z","timestamp":1768488059000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.04.06.22272763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,12]]},"references-count":41,"URL":"https:\/\/doi.org\/10.1101\/2022.04.06.22272763","relation":{},"subject":[],"published":{"date-parts":[[2022,4,12]]},"subtype":"preprint"}}